NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Jennison Associates LLC

Jennison Associates LLC cut its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 16.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,489,221 shares of the company’s stock after selling 709,333 shares during the period. Jennison Associates LLC’s holdings in NewAmsterdam Pharma were worth $122,402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Arizona State Retirement System increased its holdings in NewAmsterdam Pharma by 3.8% in the third quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after buying an additional 483 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after buying an additional 544 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its holdings in NewAmsterdam Pharma by 2.4% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 33,610 shares of the company’s stock valued at $956,000 after buying an additional 777 shares in the last quarter. Finally, Mather Group LLC. purchased a new stake in shares of NewAmsterdam Pharma during the third quarter worth about $28,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Trading Up 1.1%

Shares of NASDAQ NAMS opened at $28.75 on Thursday. NewAmsterdam Pharma Company N.V. has a 12-month low of $16.78 and a 12-month high of $42.00. The stock has a market cap of $3.30 billion, a PE ratio of -16.72 and a beta of 0.13. The company has a 50-day moving average of $32.13 and a 200 day moving average of $34.45.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.92 million. On average, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NAMS has been the subject of a number of research reports. Wall Street Zen cut shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Leerink Partners reissued an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Needham & Company LLC boosted their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.00.

Insider Activity at NewAmsterdam Pharma

In related news, Director Louis G. Lange sold 44,619 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the completion of the sale, the director owned 10,360 shares of the company’s stock, valued at approximately $315,151.20. This represents a 81.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the completion of the transaction, the insider owned 69,302 shares in the company, valued at $2,099,157.58. The trade was a 59.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,168,286 shares of company stock valued at $38,211,967. Corporate insiders own 20.84% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.